Volume | 762,834 |
|
|||||
News | - | ||||||
Day High | 11.93 | Low High |
|||||
Day Low | 10.98 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Stoke Therapeutics Inc | STOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
11.69 | 10.98 | 11.93 | 11.03 | 11.86 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
8,853 | 762,834 | US$ 11.29 | US$ 8,614,353 | - | 3.35 - 16.3999 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:12:23 | 5 | US$ 11.19 | USD |
Stoke Therapeutics (STOK) Options Flow Summary
Stoke Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
492.53M | 44.65M | - | 8.78M | -104.7M | -2.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Stoke Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STOK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.24 | 12.73 | 10.98 | 11.80 | 900,517 | -0.21 | -1.87% |
1 Month | 13.10 | 13.89 | 10.90 | 12.28 | 1,048,445 | -2.07 | -15.80% |
3 Months | 4.43 | 16.3999 | 4.09 | 11.42 | 1,312,851 | 6.60 | 148.98% |
6 Months | 3.40 | 16.3999 | 3.40 | 10.42 | 717,337 | 7.63 | 224.41% |
1 Year | 9.45 | 16.3999 | 3.35 | 9.55 | 526,489 | 1.58 | 16.72% |
3 Years | 33.29 | 41.60 | 3.35 | 13.19 | 343,190 | -22.26 | -66.87% |
5 Years | 27.21 | 71.58 | 3.35 | 17.69 | 273,985 | -16.18 | -59.46% |
Stoke Therapeutics Description
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. |